

A PRIMARY CARE GUIDE TO KEY CLINICAL QUESTIONS IN OSTEOPOROSIS MANAGEMENT

YOU ARE INVITED TO JOIN US FOR A CONTEMPORARY AND CLINICALLY RELEVANT EDUCATIONAL ACTIVITY.

This interactive program has been specifically designed to address the most frequently encountered clinical challenges in the management of patients with osteoporosis or at risk for osteoporotic fracture in the primary care setting. This activity was developed by leading Canadian Experts to provide clinicians with answers to frequently asked questions and key take-away messages that can be applied to real-world practice.



Date: January 01, 0001 Location: location name 117 silver linden dr

Program Start Time: 11:10 Program End Time: 13:11
*Meal to follow the presentation

Speaker (s): testingspk1, testingspk1 asfd, safd

RSVP: CV Only laia@chrc.net 1231231234

AGENDA & LEARNING OBJECTIVES



The following Clinical Questions will be addressed during the session:

Clinical Question:

- What parameters indicate a diagnosis of osteoporosis? How does this differ from assessment of fracture risk?

Learning Objectives: Upon completion of this activity, participants will be able to:

1. Perform risk assessments and screening for all patients at high risk for fracture
2. Explain the factors that determine osteoporotic fracture risk

Clinical Question:

- How can we best explain the impact of osteoporosis to our patients?

Learning Objectives: Upon completion of this activity, participants will be able to:

1. Describe the morbidity, mortality and economic burden of illness associated with osteoporosis in Canada
2. Explain the factors that determine osteoporotic fracture risk
3. Communicate to patients the impact of osteoporotic fractures on their quality of life and the actions they can take to reduce risk

Clinical Question:

- Do patients on glucocorticoid require osteoporosis pharmacotherapy?

Learning Objectives: Upon completion of this activity, participants will be able to:

1. Explain the impact of co-morbidities on the risk profile of patients with osteoporosis
2. Describe why glucocorticoid treatment is associated with bone loss and increased fracture risk
3. Mitigate the impact of medication-related factors which may increase the risk of bone loss and fragility fractures

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College's

This program has received an educational grant and in-kind support from Amgen Canada


CANADIAN CENTRE FOR
PROFESSIONAL DEVELOPMENT
IN HEALTH AND MEDICINE
A Division of the Canadian Heart Research Centre